In light of the heterogeneity of tumor type across the entire cohort, sensitivity analyses were performed to examine the impact of NAT excluding patients with GBC (i.e., only individuals with hilar and distal cholangiocarcinomas). The gene discussed is BRD2; the disease is neoplasm.